GovBidAlerts
← All opportunities
This notice has been superseded. See the latest notice: Levalbuterol HCL Solution (Solicitation)

Levalbuterol HCL Solution

Key dates

Posted
Aug 23, 2023
Response deadline
—
Archive date
Aug 31, 2028
Archive type
autocustom

Classification

Notice type
Award Notice
Base type
Award Notice
Set-aside
—
Set-aside code
—
PSC
6505

NAICS

  • 325412Pharmaceutical Preparation Manufacturing

    This U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions. Cross-References. Establishments primarily engaged in--

Issuing office

Department
DEPT OF DEFENSE
Sub-tier
DEFENSE LOGISTICS AGENCY
Office
DLA TROOP SUPPORT
Office code
—
Organization type
OFFICE
Office address
PHILADELPHIA, PA, 19111, USA

Place of performance

Street
—
Street 2
—
City
Cheshire
State
GB-ENG
Zip
—
Country
GBR

Contacts

Description

P00003 SPE2D222D0146 Modification to incorporate Drug Supply Chain Security Act language into solication for subject contract. P00002 SPE2D222D0146 Modification to Invoke Option Year 1. P00001 SPE2D222D0146 Modification to incorporate clause FAR 52.204-27 Prohibituion on a ByteDance Covered Application (June 2023) Contract Award for Leavalbuterol HCL Solution SPE2D222D0146

Award

Number
SPE2D222D0146
Amount
$5,687,207.30
Date
Aug 31, 2022
Awardee
Teva Pharmaceuticals USA, Inc. Parsippany NJ 07054 USA
UEI
—
Awardee address
—

Other notices in this solicitation

Similar open contracts

Similar past awards

Metadata

Notice ID
59a85b0521a249db969991decb9fa913
Full path
DEPT OF DEFENSE.DEFENSE LOGISTICS AGENCY.DLA TROOP SUPPORT
Office code
—
Ingested
May 2, 2026
Updated
May 2, 2026
Raw record
{
  "CGAC": "097",
  "City": "PHILADELPHIA",
  "Link": "https://sam.gov/workspace/contract/opp/59a85b0521a249db969991decb9fa913/view",
  "Sol#": "SPE2D221R0116",
  "Type": "Award Notice",
  "State": "PA",
  "Title": "Levalbuterol HCL Solution",
  "Active": "Yes",
  "Award$": "5687207.30",
  "Office": "DLA TROOP SUPPORT",
  "PopZip": "",
  "Awardee": "Teva Pharmaceuticals USA, Inc. Parsippany NJ 07054 USA",
  "PopCity": "Cheshire",
  "ZipCode": "19111",
  "AAC Code": "SPE2D2",
  "BaseType": "Award Notice",
  "NoticeId": "59a85b0521a249db969991decb9fa913",
  "PopState": "GB-ENG",
  "SetASide": "",
  "Sub-Tier": "DEFENSE LOGISTICS AGENCY",
  "AwardDate": "2022-08-31",
  "FPDS Code": "97AS",
  "NaicsCode": "325412",
  "PopCountry": "GBR",
  "PostedDate": "2023-08-23 12:52:34.643-04",
  "ArchiveDate": "2028-08-31",
  "ArchiveType": "autocustom",
  "AwardNumber": "SPE2D222D0146",
  "CountryCode": "USA",
  "Description": "P00003 SPE2D222D0146 Modification to incorporate Drug Supply Chain Security Act language into solication for subject contract. P00002 SPE2D222D0146 Modification to Invoke Option Year 1. P00001 SPE2D222D0146 Modification to incorporate clause FAR 52.204-27 Prohibituion on a ByteDance Covered Application (June 2023) Contract Award for Leavalbuterol HCL Solution SPE2D222D0146",
  "SetASideCode": "",
  "OrganizationType": "OFFICE",
  "PopStreetAddress": "",
  "ResponseDeadLine": "",
  "PrimaryContactFax": "",
  "AdditionalInfoLink": "",
  "ClassificationCode": "6505",
  "PrimaryContactEmail": "Phyllis.Daraio@dla.mil",
  "PrimaryContactPhone": "2157377941",
  "PrimaryContactTitle": "",
  "SecondaryContactFax": "",
  "Department/Ind.Agency": "DEPT OF DEFENSE",
  "SecondaryContactEmail": "",
  "SecondaryContactPhone": "",
  "SecondaryContactTitle": "",
  "PrimaryContactFullname": "Phyllis Daraio",
  "SecondaryContactFullname": ""
}